Razón y Saber
EspañolEnglish日本語

Johnson & Johnson After the Familiar Brands: Science, Devices and Old Obligations

The company behind a household name now centers on medicines and medical technology. Its changing portfolio and sharply different profit measures explain what JNJ shareholders actually own.

Photorealistic illustration of a healthcare professional inspecting a robotic medical instrument in a training laboratory bearing the red Johnson & Johnson wordmark.
Medicines and medical technology illustrate Johnson & Johnson’s current focus. Editorial illustration. Image generated by ChatGPT

Many people still recognize Johnson & Johnson through familiar products once kept in household cupboards. The listed company today is centered on prescription medicines and medical technology, following the separation of its consumer-health business. That change makes the historical name an imperfect guide to what its shareholders own. The current story is about scientific portfolios, hospital systems and the financial consequences of both innovation and legacy obligations.

Its equity value was approximately $655.55 billion in the November 5, 2026 snapshot. A company of that scale can fund research and acquisitions across several areas of healthcare. Size, however, does not eliminate patent expirations, product risks or litigation. Its recent accounts show why a reader needs to examine the composition of earnings rather than rely on the familiarity of the brand.

From sterile supplies to a different healthcare portfolio

Robert Wood Johnson, James Wood Johnson and Edward Mead Johnson founded the business in New Brunswick, New Jersey, in 1886. Its early work in antiseptic and sterile medical supplies connected manufacturing with safer clinical practice. That origin helps explain an enduring feature of healthcare businesses: useful products must combine technical evidence with dependable production and the confidence of medical professionals.

Over time, Johnson & Johnson expanded through scientific development and acquisitions. The separation of Kenvue in 2023 removed the consumer-health business from the present operating portfolio. Familiar consumer brands should therefore not simply be counted as current J&J businesses. Corporate continuity and continuing legal obligations also mean that selling or separating an activity does not necessarily erase every financial issue associated with its past.

The company now reports two main segments: Innovative Medicine and MedTech. The first includes prescription products in areas such as oncology, immunology and neuroscience; the second includes technologies used in cardiovascular care, surgery, vision and orthopaedics. Their commercial requirements differ. A medicine’s adoption and reimbursement follow a different path from the purchase, training and use of equipment in a hospital.

Chairman and chief executive Joaquin Duato is also overseeing another proposed portfolio change. The company plans to separate its orthopaedics business as DePuy Synthes, with management describing a targeted mid-2027 completion in its latest remarks. As of November 5, this remained a plan. The business still formed part of reported results, so future portfolio ambitions should not be substituted for the company’s actual current perimeter.

The annual profit requires an explanation

Fiscal 2025 ended on December 28, 2025. Sales reached $94.193 billion, up 6% from $88.821 billion, while net earnings were $26.804 billion compared with $14.066 billion a year earlier. Diluted earnings per share were $11.03. The increase in profit was much faster than the increase in sales, which immediately raises a question about what changed beyond ordinary product demand.

One important factor was the reversal of approximately $7 billion in previously accrued talc reserves following the dismissal of a bankruptcy-based resolution process. The prior year had included substantial talc-related charges. Those effects changed the comparison dramatically. Treating the entire rise in net earnings as a permanent improvement in the operating business would misrepresent the accounts.

Annual Innovative Medicine sales were approximately $60.4 billion, while MedTech contributed $33.8 billion. The rounded figures illustrate a substantial medical-device business alongside the larger pharmaceutical operation. They should not be added as though they were more precise than the reported consolidated total. Product mix, acquisitions and currency effects also influence growth within each segment.

The company’s annual research and development expense was $14.665 billion. Total assets were $199.210 billion. Operating cash flow reached $24.530 billion, and cash additions to property, plant and equipment were $4.832 billion. These measures describe different parts of the business: research supports future products, equipment supports operating capability and cash flow shows the funding generated during the period.

Replacing growth lost to competition

The pharmaceutical portfolio demonstrates why renewal is continuous. Stelara faced sales pressure primarily from biosimilar competition, while products including Darzalex supported growth in oncology. Losing exclusivity can reduce the commercial value of a previously important medicine even if it remains useful to patients. A pharmaceutical company must develop or obtain other sources of growth before older franchises shrink too far.

Acquisitions can accelerate that process. The April 2025 purchase of Intra-Cellular Therapies brought Caplyta into the portfolio. The contribution is economically real, but acquired growth differs from growth developed entirely within the existing business. Purchase costs, integration and the future performance of the product need to be considered alongside the additional sales.

Medical technology offers a second route to expansion, with its own competitive demands. Hospitals and specialists need evidence, training, service and reliable supplies. New equipment can require changes to clinical workflows, making commercial adoption more complex than announcing a launch. The company’s value depends on how products perform in the systems that use them, rather than the size of a potential market alone.

A quarter shaped by a new legal provision

The latest reported quarter ended September 27, 2026. Sales increased 5.9% to $25.399 billion, but net earnings fell to $210 million from $5.152 billion. Diluted earnings per share were $0.09. This was not evidence that nearly all customers disappeared. The sharp profit decline reflected major expenses, including a provision for a proposed talc litigation resolution and acquisition-related research activity.

The company recorded a $5.5 billion accrual related to the proposed resolution of ovarian-cancer talc claims. The agreement depended on conditions including participation by a specified large majority of claims. It did not resolve the separate mesothelioma docket, which remained ongoing. Johnson & Johnson disputes the allegations. A financial provision should not be presented as proof of causation or as a completed settlement of every case.

Adjusted net earnings were $6.339 billion and adjusted diluted earnings per share $2.59. Both measures also declined from the previous year’s adjusted results. Excluding amortization and special items can illuminate underlying trends, but the adjusted presentation is not a substitute for the $210 million GAAP result. Shareholders need to understand both the operating portfolio and the obligations affecting reported profit.

Innovative Medicine generated $16.757 billion in quarterly sales, and MedTech $8.642 billion. Growth came from several products and areas, while the pressure on Stelara continued. These figures demonstrate a business still selling and developing treatments and devices despite the legal charge. They also show why operating progress and financial uncertainty can exist at the same time.

The balance sheet supports choices with costs attached

At September 2026, assets totaled $197.425 billion. Cash and equivalents were $16.910 billion, while short-term loans and notes payable were $8.852 billion and long-term debt $35.799 billion. Cash resources provide flexibility, but should not be evaluated without the debt and other obligations accompanying them. Research, acquisitions, dividends and potential legal payments compete for financing.

Large purchases can bring products and scientific capabilities before internal development would deliver them. They also create intangible assets and expectations that may not be fulfilled. Trial results, commercial adoption and competitive changes can reduce an acquired asset’s value. The ability to buy a business is therefore different from the ability to earn an attractive return on the purchase price.

The proposed orthopaedics separation adds another capital-allocation decision. A more focused portfolio may allow different businesses to pursue their own priorities, but separating operations involves costs and execution. Until the transaction’s terms and completion are established, shareholders should distinguish management’s intended benefits from results already realized. The existing segments remain the starting point for financial analysis.

What the familiar ticker now means

Johnson & Johnson’s common shares trade on the New York Stock Exchange under JNJ. The dated market capitalization was roughly 24 times fiscal 2025 reported earnings, but that denominator benefited from the large reserve reversal. The ratio is consequently an incomplete guide to normal earning power. It should not be treated as a clean forward valuation or a shortcut around the legal disclosures.

The company paid $5.14 per share in dividends during 2025. Such distributions make cash returns visible to shareholders, but their sustainability depends on operating performance and competing funding requirements. Management’s October 2026 sales outlook called for $101 billion to $101.4 billion for the year. That remained guidance, rather than a completed annual result or a guarantee of future distributions.

Johnson & Johnson’s next chapter is a more concentrated healthcare company carrying a long history. Its durable value will depend on replacing aging products, making acquired science productive and managing medical technology effectively, while dealing with financial obligations from the past. Familiarity can make the business seem simple; its accounts show why understanding what remains inside the company is the more useful starting point.